Taguchi S, Kawai T, Ambe Y, Kishitani K, et al. Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis. Int J Urol 2025;32:270-276.
PMID: 39575880